AtriCure (ATRC) Receivables (2010 - 2026)

AtriCure (ATRC) has reported Receivables for 17 consecutive years, with $80.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 21.18% year-over-year to $80.0 million in Q2 2026; TTM through Jun 2026 was $80.0 million, a 21.18% increase from a year earlier, with the FY2025 full-year figure at $66.7 million, up 10.46% from the prior year.
• Receivables was $80.0 million for Q2 2026 at AtriCure, up from $71.3 million in the prior quarter.
• Over five years, Receivables peaked at $80.0 million in Q2 2026 and troughed at $40.9 million in Q1 2022.
• A 5-year average of $55.6 million and a median of $55.1 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables soared 37.45% in 2022 and advanced 6.56% in 2024, its largest moves.
• Over 5 years, Receivables stood at $42.7 million in 2022, then gained by 22.97% to $52.5 million in 2023, then increased by 14.93% to $60.3 million in 2024, then gained by 10.46% to $66.7 million in 2025, then rose by 20.0% to $80.0 million in 2026.
• The last three Receivables figures came in at $80.0 million (Q2 2026), $71.3 million (Q1 2026), and $66.7 million (Q4 2025), per Business Quant data.